• Life Technologies Corp., of Carlsbad, Calif., signed a long-term supply and exclusive licensing agreement with Novartis AG, of Basel, Switzerland, for immunotherapeutics involving T cells modified to express chimeric antigen receptors for the treatment of cancer.